SynAct Pharma AB (STO:SYNACT)

Market Cap	771.60M -17.0%
Revenue (ttm)	n/a
Net Income	-111.63M
EPS	-2.14
Shares Out	53.21M
PE Ratio	n/a
Forward PE	14.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,240
Open	14.54
Previous Close	14.54
Day's Range	14.02 - 14.98
52-Week Range	12.82 - 25.30
Beta	0.79
Analysts	n/a
Price Target	34.65 (+138.97%)
Earnings Date	May 27, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ fa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SYNACT